Free Trial
NASDAQ:MNKD

MannKind (MNKD) Stock Price, News & Analysis

MannKind logo
$5.72 +0.06 (+0.97%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About MannKind Stock (NASDAQ:MNKD)

Key Stats

Today's Range
$5.68
$5.86
50-Day Range
$5.42
$7.02
52-Week Range
$3.47
$7.63
Volume
805,406 shs
Average Volume
1.87 million shs
Market Capitalization
$1.58 billion
P/E Ratio
81.50
Dividend Yield
N/A
Price Target
$9.21
Consensus Rating
Buy

Company Overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MannKind Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

MNKD MarketRank™: 

MannKind scored higher than 57% of companies evaluated by MarketBeat, and ranked 478th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MannKind has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MannKind has only been the subject of 3 research reports in the past 90 days.

  • Read more about MannKind's stock forecast and price target.
  • Earnings Growth

    Earnings for MannKind are expected to grow by 130.00% in the coming year, from $0.10 to $0.23 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MannKind is 81.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.35.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MannKind is 81.36, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.93.

  • Read more about MannKind's valuation and earnings.
  • Percentage of Shares Shorted

    10.24% of the float of MannKind has been sold short.
  • Short Interest Ratio / Days to Cover

    MannKind has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MannKind has recently decreased by 1.16%, indicating that investor sentiment is improving.
  • Dividend Yield

    MannKind does not currently pay a dividend.

  • Dividend Growth

    MannKind does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.24% of the float of MannKind has been sold short.
  • Short Interest Ratio / Days to Cover

    MannKind has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MannKind has recently decreased by 1.16%, indicating that investor sentiment is improving.
  • News Sentiment

    MannKind has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for MannKind this week, compared to 4 articles on an average week.
  • Search Interest

    9 people have searched for MNKD on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $465,323.00 in company stock.

  • Percentage Held by Insiders

    Only 3.00% of the stock of MannKind is held by insiders.

  • Percentage Held by Institutions

    49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MannKind's insider trading history.
Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Stock News Headlines

A deadly mistake in my prediction…
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
MannKind (NASDAQ:MNKD) Coverage Initiated at Wedbush
MannKind initiated with an Outperform at Wedbush
MannKind to Present at Upcoming Investor Conferences
Top Picks 2025- MannKind MNKD
See More Headlines

MNKD Stock Analysis - Frequently Asked Questions

MannKind's stock was trading at $6.43 at the beginning of the year. Since then, MNKD stock has decreased by 11.3% and is now trading at $5.7050.
View the best growth stocks for 2025 here
.

MannKind Co. (NASDAQ:MNKD) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported $0.04 EPS for the quarter, hitting analysts' consensus estimates of $0.04. The biopharmaceutical company earned $70.08 million during the quarter, compared to analysts' expectations of $77.27 million. MannKind had a net margin of 8.07% and a negative trailing twelve-month return on equity of 17.74%.

MannKind's top institutional investors include Vanguard Group Inc. (5.82%), Nitorum Capital L.P. (3.17%), Geode Capital Management LLC (2.31%) and Arrowstreet Capital Limited Partnership (1.77%). Insiders that own company stock include Michael Castagna, Steven B Binder, Stuart A Tross, David Thomson, Alejandro Galindo and Anthony C Hooper.
View institutional ownership trends
.

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Companies (BHC), Intel (INTC) and Netflix (NFLX).

Company Calendar

Last Earnings
11/07/2024
Today
2/21/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MNKD
CUSIP
56400P20
Employees
400
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$9.21
High Stock Price Target
$12.00
Low Stock Price Target
$6.50
Potential Upside/Downside
+58.7%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Net Income
$-11,940,000.00
Pretax Margin
9.37%

Debt

Sales & Book Value

Annual Sales
$198.96 million
Book Value
($0.91) per share

Miscellaneous

Free Float
267,505,000
Market Cap
$1.60 billion
Optionable
Optionable
Beta
1.28

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:MNKD) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners